SK Bioscience Joins U.S.-Backed Ebola Project
Predicted impact: Low
Government-backed Ebola project worth ₩131B already reported in recent items.
SK BioscienceSK바이오사이언스
302440 · KOSPI · ₩302440 · SK바이오사이언스
₩32,150▲ ₩400 (1.26%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −40.90%
DCA3 ₩35,200DCA2 ₩34,550STOP ₩34,500DCA1 ₩33,850Entry ₩33,150✅ TP1 ₩31,750TP2 ₩30,400TP3 ₩28,300TP4 ₩26,250
Entry, trailing stop, targets and DCA levels of the current Squeeze! setup (paper-trading levels from a fixed rule, not advice).
- Market cap
- ₩2.5T
- Enterprise value
- ₩2.2T
- P/E
- —
- P/B
- 1.4×
- Dividend yield
- 0.0%
- ROE
- −4.9%
- Net margin
- −12.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−47.6% from the high
₩31,500Today: ₩32,000 – ₩32,750₩61,300
Returns
- 1W−9.3%
- 1M−11.8%
- 3M−1.1%
- 6M−26.3%
- YTD−33.3%
- 1Y−40.9%
- Volume today
- 66,837
- 0.9× the 20-day average
- Traded today
- ₩2.2B
- Listed shares
- 78,456,553
- EPS (12 months)
- −₩1,080
- Earnings yield −3.4%
AI research · InitiationSK Bioscience: Revenue Rebounded in 2025 but Losses Continue Through H1 2026The filings show a company whose revenue has recovered strongly from the 2024 low but which has not yet turned profitable, with margins improving only modestly.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 49: in the news.
- SentimentMixedNews: Routine filing about an investor event, with no clear good or bad news. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-10.1% over the last month; the price is below its 20-day average.
- News impactSome9 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 27: buy ₩452M at the close (17.6% of 20-day average trading value)
On its 10 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 11.6% of trading value and pointed the same way 5 of 10 times.
- 2× KODEX Leverage ₩247M
- -2× KODEX 200 Futures Inverse 2X ₩117M
- -1× KODEX Inverse ₩42M
- 2× TIGER Leverage ₩15M
- 2× TIGER 200IT Leverage ₩15M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 32 funds.
- KODEX 2000.1%
- TIGER 2000.1%
- KODEX 200TR0.1%
- KODEX Leverage2×0.1%
- RISE 2000.1%
- ACE 2000.1%
- KIWOOM 200TR0.1%
- PLUS 2000.1%
Estimated from the funds' index or underlying stock.
Futures and options
All stock futures →Futures (2026-11): 32,400
Basis +0.78% · implied rate +18.8%
Open interest 10,108 contracts
Options open interest: 14,494 calls, 9,672 puts (put/call 0.67)
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
SK Bioscience stock overview
SK Bioscience (SK바이오사이언스, KRX: 302440) is listed on KOSPI, in the Biotech & Pharma sector. SK bioscience is a South Korean vaccine company that was spun off from SK Chemicals in 2018. Its shares closed at ₩32,150 on Oct 28, 2026, up 1.26% on the day, giving it a market value of ₩2.5T.
Key facts
- Market cap
- ₩2.5T
- Sector
- Biotech & Pharma
- Latest price change
- +1.26%
- As of
- Oct 28, 2026
- Main business
- SK bioscience is a South Korean vaccine company that was spun off from SK Chemicals in 2018.
Quick answers about SK Bioscience
- What does SK Bioscience do?
- SK bioscience is a South Korean vaccine company that was spun off from SK Chemicals in 2018. It develops and commercializes its own vaccines, including seasonal flu, shingles, chickenpox, typhoid, and a COVID-19 vaccine, and also provides contract development and manufacturing (CDMO) services for global pharmaceutical companies, including through its German subsidiary IDT Biologika. The company also distributes vaccines and other products from partners such as Sanofi, with operations centered in Korea, including its Andong L HOUSE plant, and in the United States and Germany.
- What is the market cap of SK Bioscience?
- The market capitalisation of SK Bioscience was ₩2.5T at the close on Oct 28, 2026.
- Who are the largest shareholders of SK Bioscience?
- According to the latest official filings, the largest reported holders are SK Chemicals (66.73%, as of Mar 27, 2026); National Pension Service (5.50%, as of Dec 31, 2025); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.49%, as of Jul 31, 2026).
- When is the next earnings report from SK Bioscience?
- Korean companies rarely announce results dates in advance. Based on when SK Bioscience filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own SK Bioscience?
- Yes. The National Pension Service held 5.50% of SK Bioscience shares as of Dec 31, 2025.
Company profile
SK bioscience is a South Korean vaccine company that was spun off from SK Chemicals in 2018. It develops and commercializes its own vaccines, including seasonal flu, shingles, chickenpox, typhoid, and a COVID-19 vaccine, and also provides contract development and manufacturing (CDMO) services for global pharmaceutical companies, including through its German subsidiary IDT Biologika. The company also distributes vaccines and other products from partners such as Sanofi, with operations centered in Korea, including its Andong L HOUSE plant, and in the United States and Germany.
Written by AI from the company's latest annual report.
- Korean name
- SK바이오사이언스
- Sector
- Biotech & Pharma
- Business group
- SK
- CEO
- 안재용
- Founded
- Jul 2018
- Listed
- Mar 2021
- Listed shares
- 78,456,553
- Fiscal year ends
- Month 12
- Website
- www.skbioscience.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
SK Bioscience to Develop Ebola Vaccine with Overseas Partner for Bundibugyo Strain
Predicted impact: Medium
Partner development deal is about 20% of revenue, but already reported.
SK Bioscience works with global partners on Bundibugyo Ebola vaccine development and production
Predicted impact: Medium
₩131B project is about 20% of revenue, but the same news was already reported.
Recent filings
See all- Investor relations (IR) eventOct 26, 2026
- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]Aug 28, 2026
- Matters Concerning Payment Amounts by Payment Method and Payment Period, and Dispute Mediation BodiesAug 14, 2026
- Half-year report (Jun 2026)Aug 13, 2026
- Investor relations (IR) eventAug 10, 2026
Titles in Korean until English translations are added.
Also known as: SK Bioscience / SK바이오사이언스 / 302440 / KRX:302440
Source: KRX statistical information